CoStAR significantly augmented effector function of T cells responding to T cell agonists and pMHC, enhanced tumor control in a solid cancer xenograft model, even in the absence of exogenous IL-2 support, and enhanced activity of TIL derived from multiple indications. Here, IL2 is linked to neoplasm.